Drugs / MPT-0118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04859777 | Apr 2021 → Mar 2023 | metastatic malignant neoplasm, refractory malignant neoplasm | Monopteros Therapeutics Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPT-0118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04859777 ↗ |
| Known as | (S)-mepazine succinate | “This translational study supports ongoing clinical investigations (ClinicalTrials.gov Identifier: NCT04859777) of MPT-0118, (S)-mepazine succinate, in patients with advanced or...” PMID 37214210 ↗ Mar 2023 |
| Action | Inhibit | “MPT-0118 is an inhibitor of MALT1 protease” NCT04859777 ↗ |
| Route | Oral | “MPT-0118 will be administered orally twice daily (BID).” NCT04859777 ↗ |
| Target | MALT1 | “MPT-0118 is an inhibitor of MALT1 protease” NCT04859777 ↗ |